Focal nodular hyperplasia and hepatocellular adenoma: Accuracy of gadoxetic acid-enhanced MR imaging - A systematic review

Radiology

Volumn 277, Issue 2, 2015, Pages 413-423

  McInnes, Matthew D F ^a   Hibbert, Rebecca M ^a   Inácio, João R ^a   Schieda, Nicola ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GADOXETIC ACID; CONTRAST MEDIUM; GADOLINIUM PENTETATE;

CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FOLLOW UP; HUMAN; INSTITUTIONAL REVIEW; LIVER ADENOMA; LIVER BIOPSY; LIVER HYPERPLASIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; SYSTEMATIC REVIEW; ADENOMA, LIVER CELL; FOCAL NODULAR HYPERPLASIA; IMAGE ENHANCEMENT; LIVER NEOPLASMS; PROCEDURES;

ADENOMA, LIVER CELL; CONTRAST MEDIA; FOCAL NODULAR HYPERPLASIA; GADOLINIUM DTPA; HUMANS; IMAGE ENHANCEMENT; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING;

EID: 84946087114     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2015142986     Document Type: Review

References (44)

1. Grieser C, Steffen IG, Kramme IB, et al. Gadoxetic acid enhanced MRI for differentiation of FNH and HCA: a single centre experience. Eur Radiol 2014;24(6):1339-1348.
2. Denecke T, Steffen IG, Agarwal S, et al. Appearance of hepatocellular adenomas on ga-doxetic acid-enhanced MRI. Eur Radiol 2012; 22(8):1769-1775.
3. Maillette de Buy Wenniger L, Terpstra V, Beuers U. Focal nodular hyperplasia and hepatic adenoma: epidemiology and pathology. Dig Surg 2010;27(1):24-31.
4. Stoot JH, Coelen RJ, De Jong MC, Dejong C.H. Malignant transformation of hepatocellular adenomas into hepatocellular carcinomas: a systematic review including more than 1600 adenoma cases. HPB (Oxford) 2010; 12(8):509-522.
5. Barthelmes L, Tait IS. Liver cell adenoma and liver cell adenomatosis. HPB (Oxford) 2005;7(3):186-196.
6. Shanbhogue AK, Prasad SR, Takahashi N, Vikram R, Sahani DV. Recent advances in cytogenetics and molecular biology of adult hepatocellular tumors: implications for imaging and management. Radiology 2011; 258(3):673-693.
7. Veteläinen R, Erdogan D, de Graaf W, et al. Liver adenomatosis: re-evaluation of aetiology and management. Liver Int 2008;28(4): 499-508.
8. Buetow PC, Pantongrag-Brown L, Buck JL, Ros PR, Goodman ZD. Focal nodular hyper-plasia of the liver: radiologic-pathologic correlation. RadioGraphics 1996;16(2):369-388.
9. Grazioli L, Bondioni MP, Haradome H, et al. Hepatocellular adenoma and focal nodular hyperplasia: value of gadoxetic acid-enhanced MR imaging in differential diagnosis. Radiology 2012;262(2):520-529.
10. Purysko AS, Remer EM, Coppa CP, Obu-chowski NA, Schneider E, Veniero JC. Characteristics and distinguishing features of hepatocellular adenoma and focal nodular hyperplasia on gadoxetate disodium-enhanced MRI. AJR Am J Roentgenol 2012; 198(1):115-123.
11. Agarwal S, Fuentes-Orrego JM, Arnason T, et al. Infammatory hepatocellular adenomas can mimic focal nodular hyperplasia on gadoxetic acid-enhanced MRI. AJR Am J Roentgenol 2014;203(4):W408-W414.
12. Bioulac-Sage P, Rebouissou S, Thomas C, et al. Hepatocellular adenoma subtype classifcation using molecular markers and immunohistochemistry. Hepatology 2007; 46(3):740-748.
13. Balabaud C, Al-Rabih WR, Chen PJ, et al. Focal nodular hyperplasia and hepatocel-lular adenoma around the world viewed through the scope of the immunopatholog-ical classifcation. Int J Hepatol 2013;2013: 268625.
14. Bioulac-Sage P, Rebouissou S, Sa Cunha A, et al. Clinical, morphologic, and molecular features defning so-called telangiectatic focal nodular hyperplasias of the liver. Gastro-enterology 2005;128(5):1211-1218.
15. Bioulac-Sage P, Balabaud C, Zucman-Rossi J. Subtype classifcation of hepatocellular adenoma. Dig Surg 2010;27(1):39-45.
16. Nault JC, Zucman Rossi J. Molecular classifcation of hepatocellular adenomas. Int J Hepatol 2013;2013:315947.
17. Zech CJ, Bartolozzi C, Bioulac-Sage P, et al. Consensus report of the Fifth International Forum for Liver MRI. AJR Am J Roentgenol 2013;201(1):97-107.
18. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009;62(10):e1-e34.
19. Deeks JJ, Bossuyt PM, Gatsonis C, eds. Co-chrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 1.0.0. The Cochrane Collaboration, 2013. http://srdta. cochrane.org/. Edited September 13, 2013. Accessed February 22, 2015.
20. University of York. International prospective register of systematic reviews (PROS-PERO) 2014. http://www.crd.york.ac.uk/PROSPERO/. Published November 14, 2014. Accessed February 22, 2015.
21. Staunton M. Evidence-based radiology: steps 1 and 2-asking answerable questions and searching for evidence. Radiology 2007; 242(1):23-31.
22. Whiting PF, Rutjes AW, Westwood ME, Mal-lett S; QUADAS-2 Steering Group. A systematic review classifes sources of bias and variation in diagnostic test accuracy studies. J Clin Epidemiol 2013;66(10):1093-1104.
23. Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155(8):529-536.
24. Bieze M, van den Esschert J W, Nio CY, et al. Diagnostic accuracy of MRI in differentiating hepatocellular adenoma from focal nodular hyperplasia: prospective study of the additional value of gadoxetate disodium. AJR Am J Roentgenol 2012;199(1):26-34.
25. Mohajer K, Frydrychowicz A, Robbins JB, Loeffer AG, Reed TD, Reeder SB. Characterization of hepatic adenoma and focal nodular hyperplasia with gadoxetic acid. J Magn Reson Imaging 2012;36(3):686-696.
26. Portilha MA, Pedro MT, Ruivo C, Semedo LC, Marques C, Alves FC. Gd-EOB-DTPA-enhanced magnetic resonance imaging: differentiation between focal nodular hyper-plasia and hepatocellular adenoma [in Portuguese]. Acta Med Port 2011;24(Suppl 2): 531-538.
27. Fujiwara H, Sekine S, Onaya H, Shimada K, Mikata R, Arai Y. Ring-like enhancement of focal nodular hyperplasia with hepatobiliary-phase Gd-EOB-DTPA-enhanced magnetic resonance imaging: radiological-pathological correlation. Jpn J Radiol 2011;29(10):739-743.
28. Huppertz A, Haraida S, Kraus A, et al. Enhancement of focal liver lesions at ga-doxetic acid-enhanced MR imaging: correlation with histopathologic fndings and spiral CT-initial observations. Radiology 2005;234(2):468-478.
29. Sakamoto A, Hayashi H, Sakamoto I, et al. Multiple hepatocellular adenomas in a patient with glycogen storage disease type I: various enhancement patterns in MRI with Gd-EOB-DTPA. Abdom Imaging 2012;37(2): 239-243.
30. Takara K, Saito K, Kusama H, et al. Gd-EOB-DTPA-enhanced MR imaging fndings of hepatocellular adenoma: correlation with pathological fndings. Magn Reson Med Sci 2011;10(4):245-249.
31. Thomeer MG, Willemssen FE, Biermann KK, et al. MRI features of infammatory hepatocel-lular adenomas on hepatocyte phase imaging with liver-specifc contrast agents. J Magn Re-son Imaging 2014;39(5):1259-1264.
32. van Kessel CS, de Boer E, ten Kate FJ, Bro-sens LA, Veldhuis WB, van Leeuwen MS. Focal nodular hyperplasia: hepatobiliary enhancement patterns on gadoxetic-acid contrast-enhanced MRI. Abdom Imaging 2013;38(3):490-501.
33. Yoneda N, Matsui O, Kitao A, et al. He-patocyte transporter expression in FNH and FNH-like nodule: correlation with signal intensity on gadoxetic acid enhanced magnetic resonance images. Jpn J Radiol 2012;30(6):499-508.
34. Yoneda N, Matsui O, Kitao A, et al. Beta-catenin-activated hepatocellular adenoma showing hyperintensity on hepatobiliary-phase gadoxetic-enhanced magnetic resonance imaging and overexpression of OATP8. Jpn J Radiol 2012;30(9):777-782.
35. Yoon JH, Kim JY. Atypical fndings of focal nodular hyperplasia with gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging. Iran J Radiol 2014;11(1):e9269.
36. An HS, Park HS, Kim YJ, Jung SI, Jeon HJ. Focal nodular hyperplasia: characterisation at gadoxetic acid-enhanced MRI and diffusion-weighted MRI. Br J Radiol 2013;86(1028):20130299.
37. Walther Z, Jain D. Molecular pathology of hepatic neoplasms: classifcation and clinical signifcance. Pathol Res Int 2011;2011: 403929.
38. Ronot M, Bahrami S, Calderaro J, et al. Hepatocellular adenomas: accuracy of magnetic resonance imaging and liver biopsy in subtype classifcation. Hepatology 2011;53(4):1182-1191.
39. van Aalten SM, Thomeer MG, Terkivatan T, et al. Hepatocellular adenomas: correlation of MR imaging fndings with pathologic subtype classifcation. Radiology 2011;261 (1):172-181.
40. Laumonier H, Bioulac-Sage P, Laurent C, Zucman-Rossi J, Balabaud C, Trillaud H. Hepatocellular adenomas: magnetic resonance imaging features as a function of molecular pathological classifcation. Hepatol-ogy 2008;48(3):808-818.
41. Paradis V, Champault A, Ronot M, et al. Tel-angiectatic adenoma: an entity associated with increased body mass index and infam-mation. Hepatology 2007;46(1):140-146.
42. Bioulac-Sage P, Taouji S, Possenti L, Bala-baud C. Hepatocellular adenoma subtypes: the impact of overweight and obesity. Liver Int 2012;32(8):1217-1221.
43. Bashir MR, Sirlin CB, Reeder SB. On con-frmation bias in imaging research. J Magn Reson Imaging 2014 Aug 14. [Epub ahead of print]
44. Gönen M, Panageas KS, Larson SM. Statistical issues in analysis of diagnostic imaging experiments with multiple observations per patient. Radiology 2001; 221(3):763-767.